美国默克公司(MSD)已推出新的基因工程乙型肝炎疫苗,商品名为:BHEPAVACⅡ。主要是更换工程菌株和采取新的生产工艺和配制方法。用新的疫苗接种健康成人,剂量为10μg,程序为0、1和6个月,血清抗体阳转率(抗-HBs滴度≥10mIU/m)可达99%,抗体几何平均滴度(GMT)为1823mIU/ml。以2.5μg和5μg剂量分别接种婴儿及儿童,婴儿组(0～2个月)抗体阳转率为98%(2.5μg),GMT为 Merck, Inc. (MSD) has introduced a new genetically engineered hepatitis B vaccine under the trade name BHEPAVAC II. Mainly to replace the engineering strains and adopt new production technology and preparation methods. Healthy adults were immunized with the new vaccine at 10 μg for 0, 1, and 6 months. The seroconversion rate (anti-HBs titer ≥ 10 mIU / m) was 99%, and the geometric mean antibody titer (GMT ) Is 1823 mIU / ml. Infants and children were inoculated with 2.5μg and 5μg doses respectively. The positive rate of antibody positive in infants (0-2 months) was 98% (2.5μg), GMT was